Integration of pre‑existing cardiovascular comorbidity into CDK4/6 inhibitor selection for breast cancer
Therapeutic Advances in Drug Safety
Published online on January 23, 2026
Abstract
Therapeutic Advances in Drug Safety, Volume 17, January-December 2026.
Background:Cyclin-dependent kinase 4/6 (CDK4/6) inhibitors differ in cardiovascular (CV) safety. Ribociclib has been associated with a higher risk of CV adverse events compared to palbociclib and abemaciclib.Objectives:We examined patterns of CDK4/6 ...
Background:Cyclin-dependent kinase 4/6 (CDK4/6) inhibitors differ in cardiovascular (CV) safety. Ribociclib has been associated with a higher risk of CV adverse events compared to palbociclib and abemaciclib.Objectives:We examined patterns of CDK4/6 ...